US5885958A - Mu-opiate receptor peptides - Google Patents
Mu-opiate receptor peptides Download PDFInfo
- Publication number
- US5885958A US5885958A US08/824,109 US82410997A US5885958A US 5885958 A US5885958 A US 5885958A US 82410997 A US82410997 A US 82410997A US 5885958 A US5885958 A US 5885958A
- Authority
- US
- United States
- Prior art keywords
- phe
- peptide
- tyr
- formula
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 161
- 101001122476 Homo sapiens Mu-type opioid receptor Proteins 0.000 title claims description 6
- 102100028647 Mu-type opioid receptor Human genes 0.000 title claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 32
- 230000036592 analgesia Effects 0.000 claims abstract description 15
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 8
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 7
- 206010013663 drug dependence Diseases 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 6
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 31
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 31
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine group Chemical group N[C@H](CCCCN)C(=O)O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 19
- 102000005962 receptors Human genes 0.000 claims description 18
- 108020003175 receptors Proteins 0.000 claims description 18
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical group NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 8
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 8
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims 1
- 238000012875 competitive assay Methods 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract description 18
- 102000003840 Opioid Receptors Human genes 0.000 abstract description 9
- 108090000137 Opioid Receptors Proteins 0.000 abstract description 9
- 125000004122 cyclic group Chemical group 0.000 abstract description 8
- 150000001413 amino acids Chemical class 0.000 description 44
- 230000000694 effects Effects 0.000 description 22
- 230000003389 potentiating effect Effects 0.000 description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical group OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 11
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 10
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 10
- 108700025831 tyrosyl-prolyl-tryptophyl-glycinamide Proteins 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 9
- 108700023159 delta Opioid Receptors Proteins 0.000 description 9
- 102000048124 delta Opioid Receptors Human genes 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- SCIFESDRCALIIM-VIFPVBQESA-N N-methyl-L-phenylalanine Chemical compound C[NH2+][C@H](C([O-])=O)CC1=CC=CC=C1 SCIFESDRCALIIM-VIFPVBQESA-N 0.000 description 8
- 229940127240 opiate Drugs 0.000 description 8
- 210000003405 ileum Anatomy 0.000 description 7
- 229960005181 morphine Drugs 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 108020001588 κ-opioid receptors Proteins 0.000 description 6
- 108010092674 Enkephalins Proteins 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- ZHLKFJCNKZEBNG-JTQLQIEISA-N (2s)-2-(ethylamino)-3-phenylpropanoic acid Chemical compound CCN[C@H](C(O)=O)CC1=CC=CC=C1 ZHLKFJCNKZEBNG-JTQLQIEISA-N 0.000 description 4
- GZVVTACFGLQAFF-QMMMGPOBSA-N (2s)-2-amino-3-(4-nitrophenyl)propanamide Chemical compound NC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GZVVTACFGLQAFF-QMMMGPOBSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 108010065372 Dynorphins Proteins 0.000 description 4
- ZEXLJFNSKAHNFH-SYKYGTKKSA-N L-Phenylalaninamide, L-tyrosyl-L-prolyl-L-tryptophyl- Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 ZEXLJFNSKAHNFH-SYKYGTKKSA-N 0.000 description 4
- 102400000988 Met-enkephalin Human genes 0.000 description 4
- 108010042237 Methionine Enkephalin Proteins 0.000 description 4
- SCIFESDRCALIIM-UHFFFAOYSA-N N-Me-Phenylalanine Natural products CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- XIJHWXXXIMEHKW-LJWNLINESA-N endomorphin-2 Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 XIJHWXXXIMEHKW-LJWNLINESA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000004031 partial agonist Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 description 3
- HWGSOAJXZHSMGE-PMVMPFDFSA-N (2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]-n-[(2s)-1-[(2-amino-2-oxoethyl)amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(N)=O)C1=CC=C(O)C=C1 HWGSOAJXZHSMGE-PMVMPFDFSA-N 0.000 description 3
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- OBSIQMZKFXFYLV-MRVPVSSYSA-N (2r)-2-amino-3-phenylpropanamide Chemical compound NC(=O)[C@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-MRVPVSSYSA-N 0.000 description 2
- SDJCVHZDMZOUDX-LJWNLINESA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 SDJCVHZDMZOUDX-LJWNLINESA-N 0.000 description 2
- 102400000748 Beta-endorphin Human genes 0.000 description 2
- 101800005049 Beta-endorphin Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- ADBHAJDGVKLXHK-UHFFFAOYSA-N Casomorphin Chemical compound CCC(C)C(C(O)=O)NC(=O)C1CCCN1C(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C1N(CCC1)C(=O)C(N)CC=1C=CC(O)=CC=1)CC1=CC=CC=C1 ADBHAJDGVKLXHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 229930182832 D-phenylalanine Natural products 0.000 description 2
- OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical group NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 description 2
- 125000002068 L-phenylalanino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 102000001490 Opioid Peptides Human genes 0.000 description 2
- 102100024622 Proenkephalin-B Human genes 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 108010065875 beta-casomorphins Proteins 0.000 description 2
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSLQQDMGHVQLCH-HRMPSQMFSA-N chlornaltrexamine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC[C@H]5N(CCCl)CCCl)O)CC1)O)CC1CC1 OSLQQDMGHVQLCH-HRMPSQMFSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- JMNJYGMAUMANNW-FIXZTSJVSA-N dynorphin a Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 JMNJYGMAUMANNW-FIXZTSJVSA-N 0.000 description 2
- 239000006274 endogenous ligand Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- 239000003399 opiate peptide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- -1 semisolid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- SEJUQQOPVAUETF-QHLBDZCJSA-N (2r,6r,11s)-3-(cyclopropylmethyl)-6-ethyl-8-hydroxy-11-methyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2h)-one Chemical compound C([C@@]1([C@@H]([C@@H]2C(=O)C=3C1=CC(O)=CC=3)C)CC)CN2CC1CC1 SEJUQQOPVAUETF-QHLBDZCJSA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- PZWWYAHWHHNCHO-FGHAYEPSSA-N (4r,7s,10s,13r,16s,19r)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-10-(3-aminopropyl)-7-[(1r)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-3,3-dimethyl-6,9,12,15,18-pentaoxo-1,2-dithia Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(=O)N[C@@H](C(SSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)(C)C)C(=O)N[C@@H]([C@H](O)C)C(N)=O)[C@@H](C)O)C1=CC=C(O)C=C1 PZWWYAHWHHNCHO-FGHAYEPSSA-N 0.000 description 1
- GTVVZTAFGPQSPC-UHFFFAOYSA-N 4-nitrophenylalanine Chemical compound OC(=O)C(N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108700022182 D-Penicillamine (2,5)- Enkephalin Proteins 0.000 description 1
- MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102400000243 Leu-enkephalin Human genes 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920001367 Merrifield resin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- APSUXPSYBJVPPS-YAUKWVCOSA-N Norbinaltorphimine Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YAUKWVCOSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical group C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 1
- RCMWNNJFKNDKQR-UFYCRDLUSA-N Tyr-Pro-Phe Chemical group C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 RCMWNNJFKNDKQR-UFYCRDLUSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- IVHKZGYFKJRXBD-UHFFFAOYSA-N amino carbamate Chemical compound NOC(N)=O IVHKZGYFKJRXBD-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- PQKHESYTSKMWFP-WZJCLRDWSA-N beta-Funaltrexamine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3NC(=O)/C=C/C(=O)OC)CN2CC1CC1 PQKHESYTSKMWFP-WZJCLRDWSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 230000000945 opiatelike Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108700040302 phenylalanyl-cyclo(cysteinyltyrosyl-tryptophyl-ornithyl-threonyl-penicillamine)threoninamide Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to peptides that bind with high affinity and selectivity to the mu (morphine) opiate receptor; pharmaceutical preparations containing an effective amount of the peptides or salts thereof; and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing an effective amount of the peptides.
- opiates Many peptides have been found that exhibit opiate-like activity by binding to opiate receptors. Three different types of opiate receptors have been found: delta ( ⁇ ), kappa ( ⁇ ) and mu ( ⁇ ). The major putative function for opiates is their role in alleviating pain. Other areas where opiates are well-suited for use in treatment are conditions relating to gastrointestinal disorders, schizophrenia, obesity, blood pressure, convulsions, and seizures. Although the ⁇ and ⁇ receptors may also mediate analgesia, activation of ⁇ receptors is the primary and most effective means of inducing analgesia, and is the primary mechanism by which morphine acts.
- opiates, opioid peptides, and analogs thereof have demonstrated a limited degree of specificity and selectivity for the receptor or receptors to which they may bind.
- an opiate activates more than one receptor, the biological response profile for each receptor is affected, thereby potentiating a spectrum of side effects which may or may not be adverse.
- adverse side effects include heaviness of the limbs, flush or pale complexion, clogged nasal and sinus passages, dizziness, and depression. Compounds that activate ⁇ receptors frequently induce dysphoria.
- This invention relates to certain peptides and linear and cyclic analogs thereof that bind to the mu (morphine) opiate receptor with high affinity, selectivity and potency.
- These peptides have the general formula Tyr-X 1 -X 2 -X 3 wherein X 1 is Pro, D-Lys or D-Orn; X 2 is Trp, Phe or N-alkyl-Phe wherein alkyl contains 1 to about 6 carbon atoms; and X 3 is Phe, Phe-NH 2 , D-Phe, D-Phe-NH 2 or p-Y-Phe wherein Y is NO 2 , F, Cl or Br.
- This invention also relates to pharmaceutical preparations containing an effective amount of the peptides or salts thereof, and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing an effective amount of the peptides.
- the peptides of the invention have the formulas represented by:
- the last fourteen peptides listed are cyclic peptides whose linear primary amino acid sequences are given in SEQ ID NO:13 through SEQ ID NO:26.
- FIG. 1 shows the unexpectedly high affinity and selectivity for the mu opiate receptor of SEQ ID NO:1 relative to 19 peptide analogs with which it was compared.
- the Ki for the ⁇ opiate receptor is shown on the left Y-axis, expressed relative to that of Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH 2 ) (SEQ ID NO:27) (85 nM) in the solid black bars.
- the selectivity for ⁇ over ⁇ receptors ( ⁇ Ki / ⁇ Ki) is shown on the right Y-axis and with open bars.
- the dashed line from the right axis to the bar for Tyr-W-MIF-1 (*Gly) represents the 240-fold selectivity of Tyr-W-MIF-1 for ⁇ receptors.
- the arrow above the Phe analog indicates that its extraordinary affinity and selectivity were well above the range of the other compounds. Values represent the mean of 2 separate assays with each of 2 separate syntheses of the set of 20 peptides.
- This invention relates to peptides that bind to the mu (morphine) opiate receptor; pharmaceutical preparations containing an effective amount of the peptides or salts thereof; and methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence containing an effective amount of the peptides.
- the peptides of the invention have the general formula Tyr-X 1 -X 2 -X 3 wherein X 1 is Pro, D-Lys or D-Orn; X 2 is Trp, Phe or N-alkyl-Phe wherein alkyl contains 1 to about 6 carbon atoms; and X 3 is Phe, Phe-NH 2 , D-Phe, D-Phe-NH 2 or p-Y-Phe wherein Y is NO 2 , F, Cl or Br.
- Some preferred embodiments of the invention are peptides having the formulas represented by:
- the last fourteen peptides listed are cyclic peptides whose linear primary amino acid sequences are given in SEQ ID NO: 13 through SEQ ID NO:26.
- the peptide of SEQ ID NO:1 is highly selective and very potent for the ⁇ opiate receptor, with over 4000-fold weaker binding to delta receptors and over 15,000-fold weaker binding to kappa receptors, reducing the chances of side-effects.
- the peptide was isolated from brain.
- the peptide of SEQ ID NO:2 was then synthesized and shows a ⁇ receptor affinity about half that of the peptide of SEQ ID NO:1, but a selectivity that is about 3-fold higher. This peptide was also isolated from the brain.
- Both peptides of SEQ ID NO:1 and SEQ ID NO:2 differ structurally from previously known endogenous opioids in their N-terminal (Tyr-Pro) sequence, C-terminal amidation, and tetrapeptide length.
- the peptide of SEQ ID NO:1 is the first high affinity ligand to contain Trp rather than Phe as the second aromatic moiety.
- other peptides with this feature have been reported (8-10), their affinity is low, and the best known (hemorphin) is derived from enzymatic digests (8).
- ⁇ -casomorphins (11) contain the Tyr-Pro-Phe sequence found in the peptide of SEQ ID NO:2, but contain the less active Pro in position 4, and are not known to be present in neuronal tissue.
- linear and cyclic analogs of the peptides of SEQ ID NO:1 and SEQ ID NO:2 were subsequently made.
- the linear analogs are given in SEQ ID NO:3 through SEQ ID NO:12.
- the cyclic peptides have linear primary amino acid sequences given in SEQ ID NO:13 through SEQ ID NO:26, wherein the cyclization joins amino acids 2 and 4 in the sequence.
- Analogs of enkephalin and ⁇ -casomorphin have resulted in compounds with either more selective binding than the parent compound or greater activity due to increased affinity or decreased susceptibility to enzymatic degradation.
- the linear and cyclic analogs of this invention were synthesized to further improve binding, bioactivity and stability of the natural peptides.
- Linear analogs having SEQ ID NO:9 through SEQ ID NO:12 and cyclic analogs whose linear primary amino acids sequences are given in SEQ ID NO:21 through SEQ ID NO:26 have N-methylated or N-ethylated phenylalanine in position 3.
- Analogs may also be made wherein the amino acid at position 4 is p-Y-phenylalanine, wherein Y is NO 2 , F, Cl or Br, in order to enhance ⁇ receptor binding and potency (14).
- Linear analogs having SEQ ID NO:7 and SEQ ID NO:8, and cyclic analogs whose linear primary amino acids sequences are given in SEQ ID NO:17 through SEQ ID NO:20 have p-nitrophenylalanine (pNO 2 -Phe) in position 4.
- the peptides of this invention may be prepared by conventional solution-phase (15) or solid phase (16) methods with the use of proper protecting groups and coupling agents. A suitable deprotection method may then be employed to remove specified or all of the protecting groups, including splitting off the resin if solid phase synthesis is applied.
- protecting groups known in the field of peptide synthesis and recognized by conventional abbreviations therein, may be found in T. Greene, Protective Groups In Organic Synthesis, Academic Press (1981). Some preferred protecting groups that may be utilized include, N.sup. ⁇ -Boc (N.sup. ⁇ -tert-butyloxycarbonyl), N W -Z (N W -benzyloxycarbonyl), and -Obzl (-O-benzyl).
- Carbodiimide, active ester, and mixed anhydride methods may be used in the coupling reactions.
- a preferred technique uses the dicyclohexylcarbodiimide (DCC) method that can be used with or without catalytic additives such as 1-hydroxybenztriazole (HOBt) to hasten the reaction and suppress the racemization of the desired compound.
- DCC dicyclohexylcarbodiimide
- HOBt 1-hydroxybenztriazole
- the DCC and active OSu (N-hydroxysuccinimide) ester coupling reactions can be performed mostly at room temperature but may be carried out from about -78 ° C. to room temperature.
- the solvents are polar and aprotic organic solvents. Preferred solvents include dichloromethane (DCM), chloroform, and N,N'-dimethylformamide (DMF).
- DCM dichloromethane
- chloroform chloroform
- DMF N,N'-dimethylformamide
- the time required for the coupling may be between 3 and 48 hours.
- the reaction is carried out at about -10° C. to 25° C. with stirring or shaking for about 4-12 hours.
- the solid phase synthesis of linear peptides can be performed on Merrifield resins (free peptide acids), and benzhydrylamine or 4-methyl-benzhydrylamine resin with the DCC/HOBt method.
- Cyclization of the linear peptides can be performed upon substitution of an appropriate diamino carboxylic acid for Pro in position 2 in the peptides through ring closure of the 2-position side chain amino and the C-terminal carboxylic functional groups.
- the cyclization reactions can be performed with the diphenylphosphoryl azide method (17).
- Boc peptides can be performed with 100% trifluoroacetic acid (TFA) in the solution syntheses, and with 25% TFA/DCM in the solid phase syntheses in the presence of the antioxidant dithiothreitol, and m-cresol or anisole as scavenger.
- TFA trifluoroacetic acid
- the OBzl and Z protecting groups may be removed with hydrogenolysis on 10% palladium/charcoal (Pd/C) in 80% acetic acid.
- Peptides synthesized with solid phase synthesis can be split off the resin with liquid hydrogen fluoride (HF) in the presence of the proper antioxidant and scavenger.
- HF liquid hydrogen fluoride
- the amounts of the reactants utilized in the reactions, as well as the conditions required to facilitate the reactions and encourage efficient completion may vary widely depending on variations in reaction conditions and the nature of the reactants.
- the desired products may be isolated from the reaction mixture by crystallization, electrophoresis, extraction, chromatography, or other means.
- a preferred method of isolation is HPLC. All of the crude peptides can be purified with preparative HPLC, and the purity of the peptides may be checked with analytical HPLC. Purities greater than 95% of the synthesized compounds using HPLC have been obtained.
- the present invention also provides pharmaceutical preparations which contain a pharmaceutically effective amount of the peptides, or salts thereof, of this invention and a pharmaceutically acceptable carrier or adjuvant.
- the carrier may be an organic or inorganic carrier that is suitable for external, enteral or parenteral applications.
- the peptides of the present invention may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, liposomes, suppositories, intranasal sprays, solutions, emulsions, suspensions, aerosols, targeted chemical delivery systems (18), and any other form suitable for use.
- the carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, liquid or aerosol form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.
- the present invention also provides methods for providing analgesia, relief from gastrointestinal disorders such as diarrhea, and therapy for drug dependence in patients, such as mammals, including humans, which comprises administering to the patient an effective amount of the peptides, or salts thereof, of this invention.
- the diarrhea may be caused by a number of sources, such as infectious disease, cholera, or an effect or side-effect of various drugs or therapies, including those used for cancer therapy.
- the peptides of the present invention it is preferable to apply it by parenteral or enteral administration.
- the dosage of effective amount of the peptides varies from and also depends upon the age and condition of each individual patient to be treated. However, suitable unit dosages may be between about 0.01 to about 100 mg. For example, a unit dose may be from between about 0.2 mg to about 50 mg. Such a unit dose may be administered more than once a day, e.g. two or three times a day.
- Peptides containing all possible natural amino acid substitutions in position 4 of Tyr-W-MIF-1 H-Tyr-Pro-Trp-Gly-NH 2 ) (SEQ ID NO:27) were synthesized by polyethylene pin technology (19). The relative affinity and selectivity for the ⁇ receptor over the ⁇ and ⁇ receptors of the synthesized peptides were tested and compared.
- Binding of the peptides to opiate receptors was measured by inhibition of 3 H!-DAMGO (60 Ci/mmol) for ⁇ receptors, 3 H-pCl-DPDPE (49 Ci/mmol) for ⁇ receptors, or 3 H-ethylketocyclazocine (EKC) (18 Ci/mmol) in the presence of 100 nM DAMGO and DPDPE (to quench ⁇ and ⁇ binding) for ⁇ receptors (7).
- FIG. 1 shows the relative affinity of each peptide for the ⁇ receptor (solid bars).
- the peptide with Phe in the fourth position had increased affinity that considerably exceeded the scale useful for illustrating the differences among the other peptides. Its affinity estimated from two peptide sets was over 50-fold greater than that of the parent compound, Tyr-W-MIF-1, with Gly in position 4.
- the selectivity of the peptides for ⁇ over ⁇ receptors is also shown in FIG. 1 (open bars) relative to that of Tyr-W-MIF-1, which had a selectivity ratio of 240-fold in these assays.
- the parent peptide, Tyr-W-MIF-1 proved to be one of the most selective in the set.
- the selectivity ratio for ⁇ sites of the peptide with Phe in the fourth position was well above the scale for the remainder of the peptides.
- a more hydrophobic amino acid after the second aromatic residue tended to increase ⁇ receptor binding.
- the correlation between binding (IC 50 ) and the hydrophobicity of uncharged amino acids in position 4 was significant (p ⁇ 0.001). Based on the r 2 value (0.56), however, only about half of the variance in binding affinity was attributable to hydrophobicity, and the binding of the peptide of SEQ ID NO:1 was >2 standard error units stronger than predicted from the regression. This indicates that physicochemical factors in addition to hydrophobicity are important for its high binding affinity.
- the affinity and selectivity of the peptide of SEQ ID NO: 1 is also compared to currently available peptides.
- Table I shows that, in comparison to one of the most potent and ⁇ -selective analogs of enkephalin available (DAMGO), the peptide of SEQ ID NO:1 has an equal affinity and greater selectivity for the ⁇ receptor.
- Table I also shows that this peptide is more potent and selective than the peptides generally considered endogenous ligands for the ⁇ receptor ( ⁇ -endorphin and Met-enkephalin).
- This peptide is also more potent than dynorphin, which binds preferentially to the K receptor and is considered the endogenous ligand for that site but also has high affinity for the ⁇ receptor.
- the peptide of SEQ ID NO:1 has higher affinity and selectivity for the ⁇ receptor than the three major endogenous mammalian peptides with opiate activity.
- the bioactivity of the peptide of SEQ ID NO:1 was tested in vitro using the guinea pig ileum assay (21).
- the in vivo bioactivity of the peptide of SEQ ID NO:1 was examined in tests of analgesia after intracerebroventricular (icv) (22) and intrathecal (it) (23) injection to mice.
- Prolonged analgesia was also found to be induced by the peptide. About half the animals were still analgesic 1 hr after 10-20 ⁇ g of the peptide.
- the ED 50 for the endogenous pentapeptide Met-enkephalin is 75 ⁇ g, and its effects last less than 10 min (24).
- the analgesia induced by 10 ⁇ g of the peptide was reversed by a low dose of naloxone (1 mg/kg, sc) and by pretreatment for 24 h with the irreversible ⁇ -selective antagonist ⁇ -funaltrexamine (40 mg/kg), reflecting its mediation by ⁇ opiate receptors.
- the peptide was even more potent after injection by the it than the icv route with an ED 50 of 0.8 ⁇ g ⁇ 0.4 ⁇ g.
- the peptide of SEQ ID NO:1 is a very potent ⁇ analgesic.
- the affinity and selectivity of the peptide of SEQ ID NO:2 for the ⁇ receptor was tested and compared with the values obtained for the peptide of SEQ ID NO:1.
- the results for SEQ ID NO:2 are shown in Table 1.
- the peptide of SEQ ID NO:2 showed a binding profile similar to the peptide of SEQ ID NO:1, with ⁇ receptor affinity about half that of the peptide of SEQ ID NO:1 (0.69 ⁇ 0.16 nM for SEQ ID NO:2 compared with 0.36 ⁇ 0.08 nM for SEQ ID NO:1).
- the affinity at the ⁇ receptor was about 6-fold lower.
- the affinity for the ⁇ receptor is lower, but the selectivity (>13000-fold) is about 3-fold higher for SEQ ID NO:2 than for SEQ ID NO:1.
- the affinity for ic receptors was equally low for both.
- This example illustrates isolation of the peptides of SEQ ID NO:1 and SEQ ID NO:2 from brain extracts.
- An antibody was generated against the peptide of SEQ ID NO:1 and used to develop a sensitive and specific radioimmunoassay (RIA) that detects 1 pg of peptide and shows no cross-reactivity for over 40 opioid and non-opioid peptides and compounds.
- RIA radioimmunoassay
- This RIA permitted screening of HPLC fractions from bovine cortical brain extracts and isolation of the peptide by methods previously published (2,3) with minor modifications. The isolated material was subjected to six successive cycles of automated Edman degradation.
- the most prevalent PTH-amino acids were easily distinguishable from the background level of amino acids, and the first four successive cycles yielded 310 pmol Tyr, 154 pmol Pro, 72 pmol Trp, and 143 pmol Phe. After the fourth cycle no further PTH-amino acid was detected above background.
- the peptide structure was identified as Tyr-Pro-Trp-Phe and confirmed by comparison with synthetic Tyr-Pro-Trp-Phe-NH 2 (SEQ ID NO:1) and its free acid, Tyr-Pro-Trp-Phe-OH (SEQ ID NO:3).
- the elution time of the synthetic peptide amide (21.9 min) was the same as that of the isolated peptide and was clearly separated from that of the peptide acid (25.9 min).
- the isolated material from the Edman degradation steps was estimated at about 200 ng, which consisted of about 80-85% Tyr-Pro-Trp-Phe-NH 2 (SEQ ID NO:1) and 15-20% Tyr-Pro-Phe-Phe-NH 2 (SEQ ID NO:2).
- SEQ ID NO:1 the two ligands for the ⁇ receptor (Met- and Leu-enkephalin)
- Trp and Phe in the peptides of SEQ ID NO:1 and SEQ ID NO:2 represent the only two natural amino acids that maintain binding and activity in this position of the opioid pharmacophore (25,26), indicating the limit of similar natural sequences.
- Cyclic analogs to the peptides of SEQ ID NO:1 were made using the diphenyl phosphoryl azide (DPPA) method.
- the linear primary amino acid sequences of these cyclic analogs, H-Tyr-c- D-Lys-Trp-Phe! and H-Tyr-c- D-Orn-Trp-Phe! are given in SEQ ID NO:13 and SEQ ID NO:15, respectively.
- Binding affinities, in vitro bioactivities, and in vivo bioactivities of the analogs were determined by the methods previously given in Examples 1, 2 and 3, respectively, and compared with those of the parent peptides.
- the cyclic peptide whose linear primary amino acid sequence is given in SEQ ID NO:13 was found to bind to the ⁇ receptor with about 15-fold higher affinity than the peptide of SEQ ID NO:1, to have about 4-fold greater potency in the guinea pig ileum assay with a subnanomolar IC 50 and about 10-fold greater analgesic potency with an IC 50 of 0.3 ⁇ g.
- This cyclic peptide also proved more potent than morphine in producing analgesia in mice after IV injection, with an ED 50 of 0.16 ⁇ mol/kg compared to 0.3 ⁇ mol/kg for morphine.
- Partial agonists such as buprenorphine are currently being evaluated as therapeutic agents in drug dependence (27). Such compounds can have therapeutic value and less abuse potential by providing partial activation of mu-receptor mediated cellular processes and by antagonism of the opiate effects of more efficacious compounds such as morphine.
- the peptides of SEQ ID NO:3 and SEQ ID NO:4 were tested for partial agonist/antagonist effects by the method of reduction of receptor reserve in the guinea pig ileum. In this procedure, partial agonists can show full agonist activity in the untreated tissue but antagonist activity when the receptor reserve is reduced by development of tolerance to morphine or by receptor alkylating agents (21).
- Tyr-Pro-Trp-Phe-OH SEQ ID NO:3
- Tyr-Pro-Phe-Phe-OH SEQ ID NO:4
- IC 50 5 ⁇ M and 20 ⁇ M, respectively
- B-CNA beta-chlornaltrexamine
- a dose of 0.3 ⁇ M DAMGO inhibited the electrically-induced contractions by 40%.
- Tyr-Pro-Trp-Phe-OH (SEQ ID NO:3) (20 ⁇ M) 1 minute before DAMGO antagonized the effect of DAMGO; DAMGO inhibited the contractions by only 25% after pretreatment with Tyr-Pro-Trp-Phe-OH (SEQ ID NO:3), a 37% attenuation of the opiate agonist effect of DAMGO.
- Tyr-Pro-Phe-Phe-OH (SEQ ID NO:4) at 20 ⁇ M and 80 ⁇ M provided 12.5% and 35% attenuation, respectively, of the effects of DAMGO.
- compositions, methods and apparatus disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure.
- compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions, methods and apparatus and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
TABLE 1 __________________________________________________________________________ Binding affinity and selectivity of various peptides. Binding Receptor Binding Ki (nM) Selectivity Peptide μ δ κ δ/μ κ/μ __________________________________________________________________________ DAMGO 0.34 ± 0.07 190 ± 16 1300.sup.a 559 3824 SEQ ID NO:1 0.36 ± 0.08 1506 ± 174 5428 ± 474 4183 15077 SEQ ID NO:2 0.69 ± 0.16 9233 ± 201 5240 ± 460 13381 7594 β-Endorphin 4.4 ± 0.41 2.1.sup.b 2.4.sup.b 96.sup.b 1.1 46 Met-Enkephalin 5.9 ± 0.9 9.5.sup.b 0.91.sup.b 4442.sup.b 0.01 468 Dynorphin 2.0 ± 0.5 0.73.sup.b 2.4.sup.b 0.12.sup.b 3.3 0.16 Tyr-W-MIF-1.sup.a 70.9 15520 22300 219 314 __________________________________________________________________________ .sup.a Values obtained from (7). .sup.b Values obtained from (20).
__________________________________________________________________________ SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 27 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (D) OTHER INFORMATION: Phe-NH2 (phenylalanine amide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: TyrProTrpXaa (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: Phe-NH2 (phenylalanine amide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: TyrProPheXaa 1 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: TyrProTrpPhe 1 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: TyrProPhePhe 1 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: D-Phe-NH2 (D-phenylalanine amide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: TyrProTrpXaa 1 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: D-Phe-NH2 (D-phenylalanine amide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: TyrProPheXaa 1 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: pNO2-Phe-NH2 (p-nitrophenylalanineamide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: TyrProTrpXaa 1 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: pNO2-Phe-NH2 (p-nitrophenylalanineamide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: TyrProPheXaa 1 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 3 (D) OTHER INFORMATION: N-Me-Phe (N- methyl phenylalanine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (D) OTHER INFORMATION: Phe-NH2 (phenylalanine amide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: TyrProXaaXaa 1 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 3 (D) OTHER INFORMATION: N-Et-Phe (N- ethyl phenylalanine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (D) OTHER INFORMATION: Phe-NH2 (phenylalanine amide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: TyrProXaaXaa 1 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 3 (D) OTHER INFORMATION: N-Me-Phe (N- methyl phenylalanine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (D) OTHER INFORMATION: D-Phe-NH2 (D- phenylalanine amide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: TyrProXaaXaa 1 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 3 (D) OTHER INFORMATION: N-Et-Phe (N- ethyl phenylalanine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (D) OTHER INFORMATION: D-Phe-NH2 (D- phenylalanine amide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: TyrProXaaXaa 1 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Lys (D-Lysine) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: TyrXaaTrpPhe 1 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Lys (D-Lysine) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: TyrXaaPhePhe 1 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Orn (D-Ornithine) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: TyrXaaTrpPhe 1 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Orn (D-Ornithine) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: TyrXaaPhePhe 1 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Lys (D-Lysine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: pNO2-Phe-NH2 (p-nitrophenylalanineamide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: TyrXaaTrpXaa 1 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Lys (D-Lysine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: pNO2-Phe-NH2 (p-nitrophenylalanineamide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: TyrXaaPheXaa 1 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Orn (D-Ornithine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: pNO2-Phe-NH2 (p-nitrophenylalanineamide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: TyrXaaTrpXaa 1 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Orn (D-Ornithine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: pNO2-Phe-NH2 (p-nitrophenylalanineamide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: TyrXaaPheXaa 1 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Lys (D-Lysine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 3 (c) OTHER INFORMATION: N-Me-Phe (N-methyl phenylalanine) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: TyrXaaXaaPhe 1 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Orn (D-Ornithine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 3 (c) OTHER INFORMATION: N-Me-Phe (N-methyl phenylalanine) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: TyrXaaXaaPhe 1 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Lys (D-Lysine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 3 (c) OTHER INFORMATION: N-Et-Phe (N-ethyl phenylalanine) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: TyrXaaXaaPhe 1 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Orn (D-Ornithine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 3 (c) OTHER INFORMATION: N-Et-Phe (N-ethyl phenylalanine) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: TyrXaaXaaPhe 1 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Lys (D-Lysine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 3 (c) OTHER INFORMATION: N-Me-Phe (N-methyl phenylalanine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: D-Phe (D-phenylalanine) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: TyrXaaXaaXaa 1 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 2 (c) OTHER INFORMATION: D-Lys (D-Lysine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 3 (c) OTHER INFORMATION: N-Et-Phe (N-ethyl phenylalanine) (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: D-Phe (D-phenylalanine) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: TyrXaaXaaXaa 1 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4 amino acids (B) TYPE: amino acid (C) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified site (B) LOCATION: 4 (c) OTHER INFORMATION: Gly-NH2 (glycine amide) (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: TyrProTrpXaa 1 __________________________________________________________________________
Claims (25)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/824,109 US5885958A (en) | 1997-03-25 | 1997-03-25 | Mu-opiate receptor peptides |
CA2284547A CA2284547C (en) | 1997-03-25 | 1998-03-24 | Mu-opiate receptor peptides |
AU68683/98A AU6868398A (en) | 1997-03-25 | 1998-03-24 | Mu-opiate receptor peptides |
EP98914289A EP0994897A1 (en) | 1997-03-25 | 1998-03-24 | Mu-opiate receptor peptides |
PCT/US1998/005719 WO1998042732A1 (en) | 1997-03-25 | 1998-03-24 | Mu-opiate receptor peptides |
US09/252,338 US6303578B1 (en) | 1997-03-25 | 1999-02-18 | Mu-opiate receptor peptides |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/824,109 US5885958A (en) | 1997-03-25 | 1997-03-25 | Mu-opiate receptor peptides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/252,338 Division US6303578B1 (en) | 1997-03-25 | 1999-02-18 | Mu-opiate receptor peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
US5885958A true US5885958A (en) | 1999-03-23 |
Family
ID=25240605
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/824,109 Expired - Lifetime US5885958A (en) | 1997-03-25 | 1997-03-25 | Mu-opiate receptor peptides |
US09/252,338 Expired - Lifetime US6303578B1 (en) | 1997-03-25 | 1999-02-18 | Mu-opiate receptor peptides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/252,338 Expired - Lifetime US6303578B1 (en) | 1997-03-25 | 1999-02-18 | Mu-opiate receptor peptides |
Country Status (5)
Country | Link |
---|---|
US (2) | US5885958A (en) |
EP (1) | EP0994897A1 (en) |
AU (1) | AU6868398A (en) |
CA (1) | CA2284547C (en) |
WO (1) | WO1998042732A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046167A (en) * | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
US20030220323A1 (en) * | 1999-12-20 | 2003-11-27 | Francoise Stiernet | Alpha-arylethylpiperazine derivatives as neurokinin antagonists |
US6703483B1 (en) * | 1999-03-16 | 2004-03-09 | Cornell Research Foundation, Inc. | Compounds useful in pain management |
US20040248808A1 (en) * | 2003-02-04 | 2004-12-09 | Szeto Hazel H. | Methods for preventing mitochondrial permeability transition |
US20040266805A1 (en) * | 2001-09-03 | 2004-12-30 | Jessop David Swift | Inflammation modulatory compound |
US20050158373A1 (en) * | 2003-05-01 | 2005-07-21 | Szeto Hazel H. | Method and carrier complexes for delivering molecules to cells |
US20050181447A1 (en) * | 1999-11-19 | 2005-08-18 | Sharma Shubh D. | Opioid metallopeptide compositions and methods |
US20060084606A1 (en) * | 2004-01-23 | 2006-04-20 | Szeto Hazel H | Methods for reducing oxidative damage |
US20060275812A1 (en) * | 2005-06-01 | 2006-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Assay for agonists and antagonists of ion channels and for regulators of genetic expression |
US20060281070A1 (en) * | 2005-06-01 | 2006-12-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy |
US20070129306A1 (en) * | 2005-09-16 | 2007-06-07 | Szeto Hazel H | Methods for Reducing CD36 Expression |
US20090075906A1 (en) * | 2005-11-03 | 2009-03-19 | Veronique Gillon | Oligopeptides and compositions containing the oligopeptides |
US20100331265A1 (en) * | 2009-03-20 | 2010-12-30 | Tompkins Ronald G | Methods for the prevention and treatment of burn injuries and secondary complications |
US20110039766A1 (en) * | 2009-08-12 | 2011-02-17 | Szeto Hazel H | Methods for preventing or treating metabolic syndrome |
US20110065648A1 (en) * | 2009-09-15 | 2011-03-17 | Maione Theodore E | Advantageous mu-opiate receptor peptide compounds |
US20110082084A1 (en) * | 2009-10-05 | 2011-04-07 | Szeto Hazel H | Methods for the prevention or treatment of heart failure |
US20110177047A1 (en) * | 2009-08-24 | 2011-07-21 | Liping Liu | Methods and compositions for preventing or treating ophthalmic conditions |
US20110190214A1 (en) * | 2007-12-13 | 2011-08-04 | Maione Theodore E | Advantageous Salts of Mu-Opiate Receptor Peptides |
US8088727B2 (en) | 2008-02-07 | 2012-01-03 | Cornell University | Method for reducing the risk, lessening the symptom, or delaying the onset of insulin resistance by administering SS-31 |
US8143219B2 (en) | 2008-02-26 | 2012-03-27 | Cornell University | Methods for prevention and treatment of acute renal injury |
WO2012006497A3 (en) * | 2010-07-09 | 2012-05-24 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
WO2016026016A1 (en) * | 2014-08-18 | 2016-02-25 | Embrapa- Empresa Brasileira De Pesquisa Agropecuária | Opioid peptide |
US20180282370A1 (en) * | 2012-05-18 | 2018-10-04 | Cytogel Pharma, Llc | Novel therapeutic uses of mu-opiate receptor peptides |
WO2019108285A1 (en) | 2017-11-30 | 2019-06-06 | Cytogel Pharma, Llc | Novel analgesic pharmaceutical formulations and uses thereof |
US20190194397A1 (en) * | 2009-04-23 | 2019-06-27 | Pilot Polymer Technologies, Inc. | Star macromolecules for personal and home care |
WO2019100004A3 (en) * | 2017-11-17 | 2019-08-01 | Cytogel Pharma, Llc | Polymer agonists of mu opioid receptors |
US10919939B2 (en) | 2010-07-09 | 2021-02-16 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548637B1 (en) | 1998-06-18 | 2003-04-15 | Sepracor, Inc. | Ligands for opioid receptors |
US7115664B2 (en) | 2000-03-16 | 2006-10-03 | Sepracor Inc. | Peptidomimetic ligands for cellular receptors and ion channels |
WO2010004535A2 (en) * | 2008-07-10 | 2010-01-14 | Fred Nyberg | Therapeutic methods and compositions employing peptide compounds |
WO2011146922A2 (en) * | 2010-05-21 | 2011-11-24 | Cytogel Pharma, Llc | Materials and methods for treatment of inflammation |
US9994614B2 (en) * | 2014-07-24 | 2018-06-12 | Naurex, Inc. | N-methyl-D-aspartate receptor modulators and methods of making and using same |
CN112469729A (en) * | 2018-05-31 | 2021-03-09 | 悉尼大学 | Analgesic and method of use |
BR102022015847A2 (en) * | 2022-08-10 | 2024-02-15 | Univ Catolica Dom Bosco Ucdb | USE OF PEPTIDES AND FORMULATION |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4350627A (en) * | 1979-09-20 | 1982-09-21 | Farmitalia Carlo Erba S.P.A. | Biologically active peptides |
US5312899A (en) * | 1988-06-30 | 1994-05-17 | Biochem Pharma, Inc. | Dermorphin analogs |
WO1995022557A1 (en) * | 1994-02-21 | 1995-08-24 | Astra Aktiebolag | Novel opioid peptides for the treatment of pain and use thereof |
US5455230A (en) * | 1993-02-23 | 1995-10-03 | Aktiebolaget Astra | Delta opioid receptor antagonists and their use as analgesic agents |
WO1996040208A1 (en) * | 1995-06-07 | 1996-12-19 | Torrey Pines Institute For Molecular Studies | Novel mu opioid receptor ligands: agonists and antagonists |
WO1997003210A1 (en) * | 1995-07-11 | 1997-01-30 | FORFÁS (trading as BIORESEARCH IRELAND) | Glycosylase mediated detection of nucleotide sequences at candidate loci |
WO1997007130A1 (en) * | 1995-08-18 | 1997-02-27 | Astra Aktiebolag | Novel opioid peptides |
-
1997
- 1997-03-25 US US08/824,109 patent/US5885958A/en not_active Expired - Lifetime
-
1998
- 1998-03-24 WO PCT/US1998/005719 patent/WO1998042732A1/en not_active Application Discontinuation
- 1998-03-24 EP EP98914289A patent/EP0994897A1/en not_active Withdrawn
- 1998-03-24 CA CA2284547A patent/CA2284547C/en not_active Expired - Lifetime
- 1998-03-24 AU AU68683/98A patent/AU6868398A/en not_active Abandoned
-
1999
- 1999-02-18 US US09/252,338 patent/US6303578B1/en not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4350627A (en) * | 1979-09-20 | 1982-09-21 | Farmitalia Carlo Erba S.P.A. | Biologically active peptides |
US5312899A (en) * | 1988-06-30 | 1994-05-17 | Biochem Pharma, Inc. | Dermorphin analogs |
US5455230A (en) * | 1993-02-23 | 1995-10-03 | Aktiebolaget Astra | Delta opioid receptor antagonists and their use as analgesic agents |
WO1995022557A1 (en) * | 1994-02-21 | 1995-08-24 | Astra Aktiebolag | Novel opioid peptides for the treatment of pain and use thereof |
WO1996040208A1 (en) * | 1995-06-07 | 1996-12-19 | Torrey Pines Institute For Molecular Studies | Novel mu opioid receptor ligands: agonists and antagonists |
WO1997003210A1 (en) * | 1995-07-11 | 1997-01-30 | FORFÁS (trading as BIORESEARCH IRELAND) | Glycosylase mediated detection of nucleotide sequences at candidate loci |
WO1997007130A1 (en) * | 1995-08-18 | 1997-02-27 | Astra Aktiebolag | Novel opioid peptides |
Non-Patent Citations (22)
Title |
---|
Dooley, et al., Peptide Res . 8:124 137 (1995). * |
Dooley, et al., Peptide Res. 8:124-137 (1995). |
Makarov et al., Cell 88:657 666 (1997). * |
Makarov et al., Cell 88:657-666 (1997). |
Sakaguchi et al., Bull. Chem. Soc. JPN 65 No. 4 1052 1056 (1992). * |
Sakaguchi et al., Bull. Chem. Soc. JPN 65 No. 4 1052-1056 (1992). |
Sakaguchi et al., Bull. Chem. Soc. Jpn. 65:1052 1056 (1992). * |
Sakaguchi et al., Bull. Chem. Soc. Jpn. 65:1052-1056 (1992). |
Schiller et al., Advances in the Biosciences 75:85 88 (1989). * |
Schiller et al., Advances in the Biosciences 75:85-88 (1989). |
Schiller et al., Journal of Medicinal Chemistry 32:698 703 (1989). * |
Schiller et al., Journal of Medicinal Chemistry 32:698-703 (1989). |
Schiller, et al., J. Med. Chem . 32:698 703 (1989). * |
Schiller, et al., J. Med. Chem. 32:698-703 (1989). |
Schiller, et al., Proc. Natl. Acad. Sci. USA . 89:11871 11875 (1992). * |
Schiller, et al., Proc. Natl. Acad. Sci. USA. 89:11871-11875 (1992). |
Zadina et al., Nature 38613:499 502 (1997). * |
Zadina et al., Nature 38613:499-502 (1997). |
Zadina, et al., Life Sci . 55:PL 461 466 (1994). * |
Zadina, et al., Life Sci. 55:PL 461-466 (1994). |
Zadina, et al., Peptides . 15:1567 1569 (1994). * |
Zadina, et al., Peptides. 15:1567-1569 (1994). |
Cited By (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6046167A (en) * | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
US6703483B1 (en) * | 1999-03-16 | 2004-03-09 | Cornell Research Foundation, Inc. | Compounds useful in pain management |
US20040176305A1 (en) * | 1999-03-16 | 2004-09-09 | Astrazeneca Ab | Novel compounds useful in pain management |
US20050181447A1 (en) * | 1999-11-19 | 2005-08-18 | Sharma Shubh D. | Opioid metallopeptide compositions and methods |
US6979436B2 (en) | 1999-11-19 | 2005-12-27 | Palatin Technologies, Inc. | Opioid metallopeptide compositions and methods |
US20030220323A1 (en) * | 1999-12-20 | 2003-11-27 | Francoise Stiernet | Alpha-arylethylpiperazine derivatives as neurokinin antagonists |
US6916797B2 (en) * | 1999-12-20 | 2005-07-12 | Ucb, S.A. | α-arylethylpiperazine derivatives as neurokinin antagonists |
US20040266805A1 (en) * | 2001-09-03 | 2004-12-30 | Jessop David Swift | Inflammation modulatory compound |
US8404646B2 (en) | 2003-02-04 | 2013-03-26 | Cornell Research Foundation, Inc. | Methods for preventing or treating mitochondrial permeability transition |
US20100190718A1 (en) * | 2003-02-04 | 2010-07-29 | Schiller Peter W | Methods for preventing or treating mitochondrial permeability transition |
US20040248808A1 (en) * | 2003-02-04 | 2004-12-09 | Szeto Hazel H. | Methods for preventing mitochondrial permeability transition |
US7718620B2 (en) | 2003-02-04 | 2010-05-18 | Cornell Research Foundation, Inc. | Methods for preventing or treating ischemia-reperfusion injury of the kidney |
US8957030B2 (en) | 2003-02-04 | 2015-02-17 | Cornell Research Foundation, Inc. | Methods for preventing or treating mitochondrial permeability transition |
US7576061B2 (en) | 2003-02-04 | 2009-08-18 | Cornell Research Foundation, Inc. | Methods for preventing mitochondrial permeability transition |
US20070027087A1 (en) * | 2003-02-04 | 2007-02-01 | Szeto Hazel H | Methods for preventing mitochondrial permeability transition |
US8148322B2 (en) | 2003-05-01 | 2012-04-03 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
US11845807B2 (en) | 2003-05-01 | 2023-12-19 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
US10584182B2 (en) | 2003-05-01 | 2020-03-10 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
US11180574B2 (en) | 2003-05-01 | 2021-11-23 | Cornell Research Foundation Inc. | Method and carrier complexes for delivering molecules to cells |
US9315586B2 (en) | 2003-05-01 | 2016-04-19 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
US20100204448A1 (en) * | 2003-05-01 | 2010-08-12 | Szeto Hazel H | Method and carrier complexes for delivering molecules to cells |
US7704954B2 (en) | 2003-05-01 | 2010-04-27 | Cornell Research Foundation, Inc. | Method and carrier complexes for delivering molecules to cells |
US20050158373A1 (en) * | 2003-05-01 | 2005-07-21 | Szeto Hazel H. | Method and carrier complexes for delivering molecules to cells |
US9950026B2 (en) | 2004-01-23 | 2018-04-24 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
US7550439B2 (en) | 2004-01-23 | 2009-06-23 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
US7781405B2 (en) | 2004-01-23 | 2010-08-24 | Cornell Research Foundation | Methods for reducing oxidative damage |
US20060084606A1 (en) * | 2004-01-23 | 2006-04-20 | Szeto Hazel H | Methods for reducing oxidative damage |
US8618061B2 (en) | 2004-01-23 | 2013-12-31 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
US20100311664A1 (en) * | 2004-01-23 | 2010-12-09 | Szeto Hazel H | Methods for reducing oxidative damage |
US20070015711A1 (en) * | 2004-01-23 | 2007-01-18 | Szeto Hazel H | Methods for reducing oxidative damage |
US9623069B2 (en) | 2004-01-23 | 2017-04-18 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
US20060281070A1 (en) * | 2005-06-01 | 2006-12-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy |
US8003622B2 (en) | 2005-06-01 | 2011-08-23 | Darren Wolfe | Peptide biosynthesis and pain therapy |
US7825231B2 (en) | 2005-06-01 | 2010-11-02 | Darren P. Wolfe | Method of amidated peptide biosynthesis and delivery in vivo: endomorphin-2 for pain therapy |
US20110112175A1 (en) * | 2005-06-01 | 2011-05-12 | Darren P. Wolfe | Peptide biosynthesis and pain therapy |
US20060275812A1 (en) * | 2005-06-01 | 2006-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Assay for agonists and antagonists of ion channels and for regulators of genetic expression |
US8846889B2 (en) | 2005-06-01 | 2014-09-30 | Darren P. Wolfe | Peptide biosynthesis and pain therapy |
US11447523B2 (en) | 2005-09-16 | 2022-09-20 | Cornell Research Foundation, Inc. | Methods for reducing CD36 expression |
US9150614B2 (en) | 2005-09-16 | 2015-10-06 | Cornell Research Foundation, Inc. | Methods for reducing CD36 expression |
US20090264369A1 (en) * | 2005-09-16 | 2009-10-22 | Szeto Hazel H | Methods for reducing cd36 expression |
US20100317571A1 (en) * | 2005-09-16 | 2010-12-16 | Szeto Hazel H | Methods for reducing cd36 expression |
US7541340B2 (en) | 2005-09-16 | 2009-06-02 | Cornell Research Foundation, Inc. | Methods for reducing CD36 expression |
US20070129306A1 (en) * | 2005-09-16 | 2007-06-07 | Szeto Hazel H | Methods for Reducing CD36 Expression |
US8603971B2 (en) | 2005-09-16 | 2013-12-10 | Cornell Research Foundation, Inc. | Methods for reducing CD36 expression |
US7811987B2 (en) | 2005-09-16 | 2010-10-12 | Cornell Research Foundation, Inc. | Methods for reducing CD36 expression |
US8399415B2 (en) | 2005-11-03 | 2013-03-19 | Cognis Ip Management Gmbh | Oligopeptides and cosmetic compositions containing the oligopeptides |
US20090075906A1 (en) * | 2005-11-03 | 2009-03-19 | Veronique Gillon | Oligopeptides and compositions containing the oligopeptides |
US8101574B2 (en) * | 2005-11-03 | 2012-01-24 | Cognis Ip Management Gmbh | Oligopeptides and compositions containing the oligopeptides |
US8940704B2 (en) | 2007-12-13 | 2015-01-27 | Cytogel Pharma, Llc | Advantageous salts of μ-opiate receptor peptides |
US20110190214A1 (en) * | 2007-12-13 | 2011-08-04 | Maione Theodore E | Advantageous Salts of Mu-Opiate Receptor Peptides |
US20150152137A1 (en) * | 2007-12-13 | 2015-06-04 | Cytogel Pharma, Llc | Advantageous salts of mu-opiate receptor peptides |
US8088727B2 (en) | 2008-02-07 | 2012-01-03 | Cornell University | Method for reducing the risk, lessening the symptom, or delaying the onset of insulin resistance by administering SS-31 |
US11628198B2 (en) | 2008-02-26 | 2023-04-18 | Cornell University | Methods for prevention and treatment of acute renal injury |
US8143219B2 (en) | 2008-02-26 | 2012-03-27 | Cornell University | Methods for prevention and treatment of acute renal injury |
US8940696B2 (en) | 2008-02-26 | 2015-01-27 | Cornell University | Methods for prevention and treatment of acute renal injury |
US8592373B2 (en) | 2008-02-26 | 2013-11-26 | Cornell University | Methods for prevention and treatment of acute renal injury |
US9457057B2 (en) | 2009-03-20 | 2016-10-04 | The General Hospital Corporation | Methods for the prevention and treatment of burn injuries and secondary complications |
US20100331265A1 (en) * | 2009-03-20 | 2010-12-30 | Tompkins Ronald G | Methods for the prevention and treatment of burn injuries and secondary complications |
US20190194397A1 (en) * | 2009-04-23 | 2019-06-27 | Pilot Polymer Technologies, Inc. | Star macromolecules for personal and home care |
US10696798B2 (en) * | 2009-04-23 | 2020-06-30 | Pilot Polymer Technologies, Inc. | Star macromolecules for personal and home care |
US20110039766A1 (en) * | 2009-08-12 | 2011-02-17 | Szeto Hazel H | Methods for preventing or treating metabolic syndrome |
US10188692B2 (en) | 2009-08-24 | 2019-01-29 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating ophthalmic conditions |
US11612633B2 (en) | 2009-08-24 | 2023-03-28 | Stealth Biotherapeutics Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
US9549963B2 (en) | 2009-08-24 | 2017-01-24 | Stealth Biotherapeutics Corp | Methods and compositions for preventing or treating ophthalmic conditions |
US20110177047A1 (en) * | 2009-08-24 | 2011-07-21 | Liping Liu | Methods and compositions for preventing or treating ophthalmic conditions |
US8470784B2 (en) | 2009-08-24 | 2013-06-25 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
US11944662B2 (en) | 2009-08-24 | 2024-04-02 | Stealth Biotherapeutics Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
US9023807B2 (en) | 2009-08-24 | 2015-05-05 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
AU2010295996B2 (en) * | 2009-09-15 | 2014-12-18 | Cytogel Pharma, Llc | Advantageous mu-opiate receptor peptide compounds |
US20160264625A1 (en) * | 2009-09-15 | 2016-09-15 | Cytogel Pharma, Llc | Advantageous mu-opiate receptor peptide compounds |
US20110065648A1 (en) * | 2009-09-15 | 2011-03-17 | Maione Theodore E | Advantageous mu-opiate receptor peptide compounds |
US20210277057A1 (en) * | 2009-09-15 | 2021-09-09 | Cytogel Pharma, Llc | Advantageous mu-opiate receptor peptide compounds |
US11534476B2 (en) | 2009-10-05 | 2022-12-27 | Cornell University | Methods for the prevention or treatment of heart failure |
US20110082084A1 (en) * | 2009-10-05 | 2011-04-07 | Szeto Hazel H | Methods for the prevention or treatment of heart failure |
WO2012006497A3 (en) * | 2010-07-09 | 2012-05-24 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
EP3246333A1 (en) | 2010-07-09 | 2017-11-22 | The Administrators of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
US8716436B2 (en) * | 2010-07-09 | 2014-05-06 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
US20120322740A1 (en) * | 2010-07-09 | 2012-12-20 | United States Department Of Veterans Affairs | Mu opioid receptor agonist analogs of the endomorphins |
US10919939B2 (en) | 2010-07-09 | 2021-02-16 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
US20180282370A1 (en) * | 2012-05-18 | 2018-10-04 | Cytogel Pharma, Llc | Novel therapeutic uses of mu-opiate receptor peptides |
US10588934B2 (en) * | 2014-08-18 | 2020-03-17 | Embrapa-Empresa Brasileira De Pesquisa Agropecuaria | Opioid peptide |
US20170232057A1 (en) * | 2014-08-18 | 2017-08-17 | Embrapa- Empresa Brasileira De Pesquisa Agropecuár ia | Opioid peptide |
WO2016026016A1 (en) * | 2014-08-18 | 2016-02-25 | Embrapa- Empresa Brasileira De Pesquisa Agropecuária | Opioid peptide |
US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
US11603385B2 (en) | 2017-06-24 | 2023-03-14 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
JP2021503481A (en) * | 2017-11-17 | 2021-02-12 | サイトジェル ファーマ リミテッド ライアビリティ カンパニー | Polymer agonist of μ opioid receptor |
WO2019100004A3 (en) * | 2017-11-17 | 2019-08-01 | Cytogel Pharma, Llc | Polymer agonists of mu opioid receptors |
US12037416B2 (en) | 2017-11-17 | 2024-07-16 | Cytogel Pharma, Llc | Polymer agonists of mu opioid receptors |
CN111683654A (en) * | 2017-11-30 | 2020-09-18 | 细胞凝胶制药有限责任公司 | Novel analgesic pharmaceutical preparation and use thereof |
WO2019108285A1 (en) | 2017-11-30 | 2019-06-06 | Cytogel Pharma, Llc | Novel analgesic pharmaceutical formulations and uses thereof |
AU2018375087B2 (en) * | 2017-11-30 | 2023-10-05 | Cytogel Pharma, Llc | Novel analgesic pharmaceutical formulations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US6303578B1 (en) | 2001-10-16 |
AU6868398A (en) | 1998-10-20 |
CA2284547C (en) | 2011-04-05 |
EP0994897A1 (en) | 2000-04-26 |
WO1998042732A1 (en) | 1998-10-01 |
CA2284547A1 (en) | 1998-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5885958A (en) | Mu-opiate receptor peptides | |
EP0833652B1 (en) | Novel kappa receptor selective opioid peptides | |
Schiller et al. | Synthesis and in vitro opioid activity profiles of DALDA analogues | |
US5919897A (en) | MU opioid receptor ligands: agonists and antagonists | |
KR19990037677A (en) | The novel opioid peptide | |
US5780589A (en) | Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof | |
Gicquel et al. | Structure-activity study of neuropeptide FF: contribution of N-terminal regions to affinity and activity | |
Okada et al. | Structural studies of [2′, 6′-dimethyl-L-tyrosine1] endomorphin-2 analogues: enhanced activity and cis orientation of the Dmt-Pro amide bond | |
US5602100A (en) | Dermorphin analogs having pharmacological activity | |
Rivier et al. | Gonadotropin-releasing hormone antagonists: novel members of the azaline B family | |
Fichna et al. | Characterization of antinociceptive activity of novel endomorphin-2 and morphiceptin analogs modified in the third position | |
WO2006064530A2 (en) | Dermorphin analogs with analgesic activity | |
US4103005A (en) | Novel-enkephalin analogs | |
AU707245B2 (en) | Novel MU opioid receptor ligands: agonists and antagonists | |
Zadina et al. | Mu-Opiate receptor peptides | |
WO1990000564A1 (en) | Peptides with extraordinary opioid receptor selectivity | |
AU688040B2 (en) | New opioid peptide analogs with mixed MU agonist/delta antagonist properties | |
SCHMIDT et al. | Effect of aromatic amino acid substitutions in the 3‐position of cyclic β‐casomorphin analogues on μ‐opioid agonist/δ‐opioid antagonist properties | |
US20210002231A1 (en) | Hybrid mu opioid receptor and neuropeptide ff receptor binding molecules, their methods of preparation and applications in therapeutic treatment | |
Dawidowska et al. | Potent bradykinin antagonists containing N‐benzylglycine or N‐benzyl‐l‐alanine in position 8 | |
US6753317B1 (en) | Dmt-Tic di- and tri-peptide derivatives and related compositions and methods of use | |
PL226256B1 (en) | N-substituted cyclic amides of dermorfin ureido analogues and methods for their preparation | |
Rew | Synthesis and biological activities of heteroatom-bridged cyclic enkephalin analogs | |
MXPA98001192A (en) | New opioid peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ADMINSTRATORS OF THE TULANE EDUCATIONAL FUND, THE, Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZADINA, JAMES E.;KASTIN, ABBA J.;HACKLER, LASZLO;REEL/FRAME:008642/0810 Effective date: 19970326 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: DEPARTMENT OF VETERANS AFFAIRS, DISTRICT OF COLUMB Free format text: CONFIRMATORY LICENSE;ASSIGNORS:ZADINA, JAMES E.;KASTIN, ABBA J.;REEL/FRAME:014675/0609 Effective date: 19961217 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |